Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 8/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL716612 | 0.91 | NPC1 (0.46) | POLBRAB9ANPC1LMNAMEN1 | |
| SCHEMBL716840 | 0.85 | HSP90AA1 (0.45) | — | |
| SCHEMBL166804 | 0.82 | NPC1 (0.56) | POLBRAB9ANPC1LMNAMEN1 | |
| SCHEMBL715025 | 0.82 | NAA50 (0.38) | POLBHSD17B10KDM4EHTT | |
| SCHEMBL166110 | 0.81 | POLB (0.47) | POLBRAB9ANPC1LMNAMEN1 | |
| SCHEMBL166512 | 0.79 | POLB (0.57) | POLBRAB9ANPC1LMNAHSD17B10 | |
| SCHEMBL717696 | 0.77 | RIPK1 (0.45) | ALDH1A1 | |
| SCHEMBL715961 | 0.75 | BACE1 (0.55) | — | |
| SCHEMBL10140476 | 0.75 | NPC1 (0.57) | POLBRAB9ANPC1LMNAMEN1 | |
| SCHEMBL716412 | 0.74 | BACE1 (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | POLB 1391/4885RAB9A 3788/4885NPC1 120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.